AbCellera Biologics Accounts Payable

As of the most recent data (June 2026), ABCL shows a accounts payable of $12M. That compares with $32M in the prior-year period — down 62.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ABCL's accounts payable is now $12M (was $32M) — a 62.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether AbCellera Biologics is outperforming or lagging.

Tracking ABCL's accounts payable over time shows whether AbCellera Biologics is scaling, shrinking, or reshaping that part of the business. The current reading is $12M That compares with $32M in the prior-year period — down 62.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has AbCellera Biologics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $12M) with ownership activity and broader fundamentals.